<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496779</url>
  </required_header>
  <id_info>
    <org_study_id>TOTAL</org_study_id>
    <nct_id>NCT03496779</nct_id>
  </id_info>
  <brief_title>Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine</brief_title>
  <official_title>A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open label, multicenter phase 2 study. The primary objective of the study is&#xD;
      to determine the efficacy of brentuximab vedotin in patients treated by gemcitabine for&#xD;
      relapsed or refractory peripheral T-cell lymphoma in term of overall response rate assessed&#xD;
      after 4 cycles of treatment according to the international response criteria for malignant&#xD;
      lymphoma (Lugano Classification 2014 - CT-Based Response).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, there is no standard treatment for patients with recurrent or refractory&#xD;
      peripheral T-cell lymphoma who relapse after a first line of cyclophosphamide,&#xD;
      hydroxydaunomycin, oncovin, and prednisone (CHOP) treatment.&#xD;
&#xD;
      Chemotherapies such as gemcitabine are used as monotherapy but the results alone are&#xD;
      insufficient. In addition, there is no approved monotherapy in the European Union, with the&#xD;
      exception of brentuximab vedotin in refractory or recurrent large systemic anaplastic&#xD;
      lymphomas.&#xD;
&#xD;
      Stem cell transplantation may be an option for patients who respond to a second line of&#xD;
      treatment or a subsequent line of treatment, but conditions for being eligible for&#xD;
      transplantation, including long-term remission, are infrequent.&#xD;
&#xD;
      Brentuximab vedotin (BV) is a targeted treatment directed against a protein, cluster of&#xD;
      differentiation antigen 30 (CD30), present on the surface of lymphoma cells. It allows&#xD;
      chemotherapy to enter directly into the lymphoma cell. The CD30 protein is variably expressed&#xD;
      in patients with relapsed or refractory T-cell lymphoma; about 50% of patients have&#xD;
      significant expression.&#xD;
&#xD;
      Data from clinical studies with brentuximab vedotin suggest that the addition of this&#xD;
      treatment to gemcitabine may be more successful than gemcitabine alone.&#xD;
&#xD;
      The main hypothesis is a 15% increase in responder patients after 4 cycles of treatment with&#xD;
      brentuximab vedotin and gemcitabine. The main objective of the study is therefore to&#xD;
      determine the overall response rate after 4 cycles of treatment according to the criteria of&#xD;
      Lugano 2014 (response based on CT-scan).&#xD;
&#xD;
      The secondary objectives will focus on the efficacy of brentuximab vedotin: complete response&#xD;
      rate, response time for responder patients, time to failure of treatment, time to next&#xD;
      treatment and overall survival, efficacy of brentuximab vedotin maintenance: survival&#xD;
      progression-free, response time, overall survival, overall response rate based on positron&#xD;
      emission tomography (PET)-scan and brentuximab vedotin toxicity in patients treated with&#xD;
      gemcitabine and in maintenance therapy.&#xD;
&#xD;
      The duration of the study is estimated to be 4.5 years including follow-up with an estimated&#xD;
      recruitment period of 1.5 years. 70 patients will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 10, 2018</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>This study is an open label, multicenter phase 2 study. Patients treated with gemcitabine will receive brentuximab vedotin (GBv) for 4 cycles of induction.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>rate of patient in Complete/Partial response according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>% of patient who did not progressed according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>4.5 years</time_frame>
    <description>% of patient who did not progressed according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>rate of patient in Complete Response (CR)according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>duration between the Complete/Partial Response and the Progression according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response) = duration between the Complete/Partial Response and the Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>4.5 years</time_frame>
    <description>duration between the Complete/Partial Response and the Progression according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response) = duration between the Complete/Partial Response and the Progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Treatment Failure (TTF)</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>duration between the inclusion and the premature end of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to next treatment</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>Duration between the end of the studied treatment and the beginning of a new one after progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
    <description>% of patient still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>4.5 years</time_frame>
    <description>% of patient still alive</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>4.5 years</time_frame>
    <description>rate of patient in Complete/Partial response according to the international response criteria for malignant lymphoma (Lugano Classification 2014 - CT-Based Response).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAE) during the induction period</measure>
    <time_frame>16 weeks = 4 cycles or permanent treatment discontinuation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Serious Adverse Events (SAE) during the maintenance period</measure>
    <time_frame>36 weeks = 12 cycles or permanent treatment discontinuation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">71</enrollment>
  <condition>Refractory Peripheral T-Cell Lymphoma</condition>
  <condition>Relapsed Peripheral T-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients treated with gemcitabine will receive Brentuximab Vedotin-induction for 4 cycles of induction.&#xD;
Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation.&#xD;
Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with Brentuximab Vedotin-maintenance every 3 weeks for 12 infusions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin - induction</intervention_name>
    <description>Brentuximab vedotin 1.8 mg/kg at D8 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Adcetris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine 1000 mg/m² at D1 and D15 of a 28-day cycle - 4 cycles = 16 weeks for combined chemotherapy</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brentuximab Vedotin - maintenance</intervention_name>
    <description>Patients who will obtain partial or complete response and who will not be eligible for transplant will receive maintenance therapy with brentuximab vedotin every 3 weeks for 12 infusions.&#xD;
Brentuximab vedotin 1.8 mg/kg at D1 of a 21-day cycle - 12 cycles = 36 weeks for maintenance therapy</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Adcetris</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous or allogeneic stem cell transplantation</intervention_name>
    <description>Patients who will obtain partial or complete response and who will be eligible for transplant will receive autologous or allogeneic stem cell transplantation</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females of 18 years to 80 years of age;&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent document prior to any study&#xD;
             related assessment or procedure;&#xD;
&#xD;
          -  Patients able to adhere to the study visit schedule and protocol requirements;&#xD;
&#xD;
          -  Patients with histologically proven, CD30 positive (at least 5% of cells according to&#xD;
             local examination) peripheral T-cell lymphoma (PTCL) according to the 2016 World&#xD;
             Health Organization (WHO) classification for whom gemcitabine treatment is expected. A&#xD;
             biopsy at relapse is highly recommended;&#xD;
&#xD;
          -  Patients who have evidence of relapsed disease after at least one line (and no more&#xD;
             than three lines) of treatment or who were refractory to a first or subsequent line of&#xD;
             treatment;&#xD;
&#xD;
          -  Patients with Ann Arbor stage I - IV;&#xD;
&#xD;
          -  Patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2;&#xD;
&#xD;
          -  Patients with at least one measurable disease, i.e. one nodal or extra-nodal lesion of&#xD;
             1.5 cm or more;&#xD;
&#xD;
          -  Negative pregnancy test for females of childbearing potential (FCBP);&#xD;
&#xD;
          -  Female patients of child bearing potential must use an effective method of birth&#xD;
             control (i.e. hormonal contraceptive, intrauterine device, diaphragm with spermicide,&#xD;
             condom with spermicide or abstinence) during treatment period and 6 months thereafter.&#xD;
&#xD;
          -  Males must use an effective method of birth control during treatment period and 6&#xD;
             months thereafter.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any significant medical condition or laboratory abnormality unrelated to PTCL, or&#xD;
             psychiatric illness that would prevent the patient from participating in the study and&#xD;
             from signing the informed consent form;&#xD;
&#xD;
          -  Any condition that confounds the ability to interpret data from the study;&#xD;
&#xD;
          -  Other types of lymphomas, e.g. B-cell lymphoma;&#xD;
&#xD;
          -  Central nervous system and/or meningeal involvement by PTCL;&#xD;
&#xD;
          -  Signs or symptoms of Progressive Multifocal Leukoencephalopathy;&#xD;
&#xD;
          -  Preexistent peripheral neuropathy ≥ grade 2, whatever the cause;&#xD;
&#xD;
          -  Contraindication to any drug contained in the chemotherapy regimen;&#xD;
&#xD;
          -  Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient&#xD;
             contained in the drug formulation of brentuximab vedotin;&#xD;
&#xD;
          -  Subjects with HIV or HTLV1 positivity;&#xD;
&#xD;
          -  Subjects with active hepatitis B or C. Chronic carriers of hepatitis B without&#xD;
             hepatitis B virus (HBV) DNA positive blood are eligible. Subjects with non-active&#xD;
             hepatitis C (with normal transaminases) are eligible;&#xD;
&#xD;
          -  Chronic or acute, clinically significant, untreated bacterial, viral or fungal&#xD;
             infection;&#xD;
&#xD;
          -  Any of the following laboratory abnormalities:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt; 1500 cells/mm3 (1.5 x 109/L);&#xD;
&#xD;
               2. Platelet count &lt;75,000/mm3 (75 x 109/L);&#xD;
&#xD;
               3. Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥ 3.0 x&#xD;
                  upper limit of normal (ULN). AST or ALT may be elevated up to 5 x ULN if their&#xD;
                  elevation can be ascribed to the presence of hematologic/solid tumor in the&#xD;
                  liver;&#xD;
&#xD;
               4. Serum total bilirubin &gt; 1.5 x ULN;&#xD;
&#xD;
               5. Serum lipase level &gt; 2 x ULN;&#xD;
&#xD;
               6. Serum creatinine &gt; 2.0 mg/dL and/or creatinine clearance or calculated creatinine&#xD;
                  clearance &lt; 40 mL/minute;&#xD;
&#xD;
               7. Hemoglobin &lt; 8g/dL;&#xD;
&#xD;
          -  Active malignancies other than PTCL requiring systemic treatment;&#xD;
&#xD;
          -  Previous treatment with brentuximab vedotin;&#xD;
&#xD;
          -  Previous treatment with gemcitabine;&#xD;
&#xD;
          -  Pregnant or lactating females or women of childbearing potential not willing to use an&#xD;
             adequate method of birth control for the duration of the study;&#xD;
&#xD;
          -  Known history of any of the following cardiovascular conditions:&#xD;
&#xD;
               1. Myocardial infarction within 2 years of enrollment&#xD;
&#xD;
               2. New York Heart Association (NYHA) Class III or IV heart failure&#xD;
&#xD;
               3. Evidence of current uncontrolled cardiovascular conditions, including cardiac&#xD;
                  arrhythmias, congestive heart failure (CHF), angina, or electrocardiographic&#xD;
                  evidence of acute ischemia or active conduction system abnormalities&#xD;
&#xD;
               4. Recent evidence (within 6 months before first dose of study drug) of a&#xD;
                  left-ventricular ejection fraction &lt;50%&#xD;
&#xD;
          -  Patients that have not completed any prior treatment chemotherapy and/or other&#xD;
             investigational agents within at least 5 half-lives of last dose of that prior&#xD;
             treatment;&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 3 years before the first dose or&#xD;
             previously diagnosed with another malignancy and have evidence of residual disease.&#xD;
             Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not&#xD;
             excluded if they have undergone complete resection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard DELARUE, MD</last_name>
    <role>Study Chair</role>
    <affiliation>APHP - Hôpital Necker</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivier TOURNILHAC, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Estaing - Clermont Ferrant</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Stuivenberg</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A. Z. Sint-Jan</name>
      <address>
        <city>Bruges</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Universitaire Saint LUC</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jules Bordet</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ULB Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU UCL Namur</name>
      <address>
        <city>Yvoir</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IHBN - CHU Cote de Nacre</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Angers</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH d'Avignon - Hôpital Henri Dufaut</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Côte Basque</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Besançon - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Chambéry</name>
      <address>
        <city>Chambery</city>
        <zip>73011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon - Hôpital le Bocage</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Versailles - Hopital André Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH du Mans</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon Cedex 8</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Annecy Genevois</name>
      <address>
        <city>Metz-Tessy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Mulhouse Sud Alsace</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Nancy - Brabois</name>
      <address>
        <city>Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre François Magendie - Hôpital du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers - Hôpital de la Milétrie</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU De Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri BECQUEREL</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Valenciennes</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.lysarc.org/</url>
    <description>Website of LYSARC</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 5, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Brentuximab Vedotin</keyword>
  <keyword>T-cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Brentuximab Vedotin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

